Acetylated tyrosine – Kodiac biolabs

Plain-language summaryIntrigue 42 / 100

N-acetyl-L-tyrosine (NALT) is the acetylated form of tyrosine, marketed as more bioavailable than free tyrosine. Evidence for the bioavailability claim is limited but the compound is widely used in nootropic formulations. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

11/100

Disproven bioavailability claim makes NALT strictly inferior to plain L-tyrosine as a research substrate

Look, we’ll be direct: NALT is essentially a marketing artifact. The pitch has always been that acetylation improves tyrosine’s bioavailability and CNS penetration, making it a smarter substrate for catecholamine synthesis than plain L-tyrosine. The problem is that human pharmacokinetic data doesn’t support this. Tissue deacetylases do convert NALT to free tyrosine, but the efficiency is poor enough that a substantial fraction of the administered dose is excreted as intact NALT in urine without ever contributing to tyrosine pools. You’re not getting more tyrosine to the brain; you’re getting less tyrosine to anywhere, with the difference ending up in the toilet.

This isn’t a subtle finding or a contested edge case. The PK literature is pretty clear: L-tyrosine itself achieves better plasma tyrosine elevation on an equal milligram basis. The acetylated form was supposed to behave as a pro-drug that shed its acetyl group efficiently in peripheral tissue. It doesn’t. Thats the whole story.

From a research standpoint, theres almost nothing useful here. If your question involves catecholamine substrate loading, you want L-tyrosine. If your question involves measuring how specific deacetylase activity affects amino acid bioavailability, NALT could theoretically serve as a narrow probe substrate, but that’s an extremely specific experimental design and not a general research tool. We don’t know of serious research programs using NALT for that purpose, and we wouldn’t expect to find them.

The mechanism column is equally thin. Catecholamine synthesis from tyrosine via tyrosine hydroxylase is foundational biochemistry understood for decades. There’s no novel angle here, no dual-target story, no surprising receptor biology. It’s a substrate for a well-understood pathway, and it’s a worse substrate than the unmodified amino acid. That combination, unremarkable mechanism plus inferior pharmacokinetics, is about as uncompelling as a research compound gets.

Differentiation is near zero, and it’s negative where it matters. NALT competes directly with L-tyrosine in the catecholamine support space and loses on PK grounds. It also competes with phenylalanine as an upstream precursor, and loses there too. We can’t identify a single application where NALT is the correct choice over a readily available comparator.

Honestly, this is one of the cleaner examples of supplement marketing outrunning the science. The acetylation story sounded plausible, vendors ran with it for years, and the actual PK work eventually showed the premise was wrong. Its still widely sold. Researchers looking at catecholamine biology should skip NALT entirely and work with L-tyrosine directly. Nothing here to chase.

Novelty: 8
Mechanism promise: 7
In-category differentiation: 8
Evidence quality: 25
Translational signal: 10
Research bench value: 12

Rationale NALT’s core premise, that acetylation improves CNS delivery of tyrosine, is contradicted by human PK data showing poor deacetylation and urinary excretion of intact NALT; all six axes score near floor because the compound is demonstrably worse than its unmodified comparator and carries no compensating research utility.

Acetylated tyrosine

An N-acetylated form of L-tyrosine with claimed superior bioavailability that has not been validated in pharmacokinetic studies.

Abstract

N-Acetyl-L-Tyrosine (NALT) is an N-acetylated form of L-tyrosine sold as a dietary supplement with claims of improved bioavailability and CNS penetration compared with L-tyrosine itself. Pharmacokinetic studies in humans show that NALT is poorly converted to free tyrosine by tissue deacetylases (the bulk is excreted as NALT in urine without contributing to tyrosine pools). The compound is therefore likely to be inferior to L-tyrosine on a milligram basis for catecholamine support applications, despite vendor claims. Investigators should generally use L-tyrosine itself.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-146Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Acetylated tyrosine

N-Acetyl-L-Tyrosine

Abstract

Read the full monograph